1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Proton Pump

Proton Pump

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101646
    Saviprazole
    Inhibitor
    Saviprazole is a Proton Pump inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux.
    Saviprazole
  • HY-17021S1
    Esomeprazole-d3
    Inhibitor
    Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
    Esomeprazole-d<sub>3</sub>
  • HY-B0656AS2
    Rabeprazole-d4 potassium
    Inhibitor
    Rabeprazole-d4 potassium is deuterated labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole-d<sub>4</sub> potassium
  • HY-B0113S1
    Omeprazole-d3-1
    Inhibitor
    Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].
    Omeprazole-d<sub>3</sub>-1
  • HY-13662C
    (S)-Lansoprazole
    Inhibitor 99.17%
    (S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    (S)-Lansoprazole
  • HY-162264
    Tubulin polymerization/V-ATPase-IN-1
    Inhibitor
    Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration.
    Tubulin polymerization/V-ATPase-IN-1
  • HY-N2033R
    Chebulinic acid (Standard)
    Inhibitor
    Chebulinic acid (Standard) is the analytical standard of Chebulinic acid. This product is intended for research and analytical applications. Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
    Chebulinic acid (Standard)
  • HY-A0213
    Tiludronate
    Inhibitor
    Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
    Tiludronate
  • HY-101664S
    Ilaprazole-d3
    Inhibitor
    Ilaprazole-d3 (IY-81149-d3) is deuterium-labeled Ilaprazole (HY-101664).
    Ilaprazole-d<sub>3</sub>
  • HY-17623S
    Tegoprazan-d6
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.
    Tegoprazan-d<sub>6</sub>
  • HY-123370
    FR-167356
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss.
    FR-167356
  • HY-123095
    TS 155-2
    Inhibitor
    TS 155-2 (JBIR 100), an antimicrobial agent, is a Bafilomycin analogue and an antibiotic. TS 155-2 can be isolated from a culture of Streptomyces sp. TS 155-2 inhibits V-ATPase activity. V-ATPase is correlated with an increasing number of diseases such as osteopetrosis, male infertility and renal acidosis.
    TS 155-2
  • HY-A0213AS
    Tiludronate-d5 sodium
    Inhibitor
    Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
    Tiludronate-d<sub>5</sub> sodium
  • HY-17507AR
    Pantoprazole sodium (Standard)
    Inhibitor
    Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium (Standard)
  • HY-W013186S
    Lansoprazole sulfide-d4
    Inhibitor ≥99.0%
    Lansoprazole sulfide-d4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth[1].
    Lansoprazole sulfide-d<sub>4</sub>
  • HY-105220
    WY-47766
    Inhibitor
    WY-47766(OST-766) is aproton pumpinhibitor.
    WY-47766
  • HY-17507BR
    Pantoprazole sodium hydrate (Standard)
    Inhibitor
    Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium hydrate (Standard)
  • HY-N7031R
    (±)​-​Vasicine (Standard)
    Inhibitor
    (±)?-Vasicine (Standard) is the analytical standard of (±)?-Vasicine. This product is intended for research and analytical applications. (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect.
    (±)​-​Vasicine (Standard)
  • HY-W008614R
    Lansoprazole sulfone (Standard)
    Inhibitor
    Lansoprazole sulfone (Standard) is the analytical standard of Lansoprazole sulfone. This product is intended for research and analytical applications. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.
    Lansoprazole sulfone (Standard)
  • HY-17023R
    Esomeprazole sodium (Standard)
    Inhibitor
    Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole sodium (Standard)
Cat. No. Product Name / Synonyms Application Reactivity